Efficacy Evaluation and Mechanisms of Youguiyin in Rats with Pulmonary Fibrosis

TANG Lei; SHEN Meng-meng; ZHU Man; KANG Di; LI Yu; LI Jian; ZHANG Lin; NIU Jian-zhao; WANG Ji-feng; LI Ya-dong

doi:10.13422/j.cnki.syfjx.20181210

您当前的位置：

首页 >

文章列表页 >

Efficacy Evaluation and Mechanisms of Youguiyin in Rats with Pulmonary Fibrosis

更新时间：2024-01-04

- Efficacy Evaluation and Mechanisms of Youguiyin in Rats with Pulmonary Fibrosis
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 24, Issue 13, Pages: 93-99(2018)
- 作者机构：
- 作者简介：
- 基金信息：
- DOI：10.13422/j.cnki.syfjx.20181210
  CLC： R285.5
- Published：2018
- 稿件说明：
移动端阅览
TANG Lei, SHEN Meng-meng, ZHU Man, et al. Efficacy Evaluation and Mechanisms of Youguiyin in Rats with Pulmonary Fibrosis[J]. Chinese journal of experimental traditional medical formulae, 2018, 24(13): 93-99.
DOI：

TANG Lei, SHEN Meng-meng, ZHU Man, et al. Efficacy Evaluation and Mechanisms of Youguiyin in Rats with Pulmonary Fibrosis[J]. Chinese journal of experimental traditional medical formulae, 2018, 24(13): 93-99. DOI： 10.13422/j.cnki.syfjx.20181210.

摘要

目的：探讨温补肾阳的代表方剂右归饮对博莱霉素致肺纤维化大鼠的药效作用和相关机制。方法：SPF级雄性SD大鼠25只，采用随机数字法，将SD大鼠分为正常组、模型组、右归饮高、中、低剂量组，每组各5只。气管内注射博莱霉素（5 mg·kg-1）建立实验性肺纤维化模型，并于造模后第15天开始灌胃高、中、低剂量（20，10，5 g·kg-1）右归饮，连续给14 d。用动物肺功能仪检测大鼠吸气阻力（Ri），呼气阻力（Re），肺顺应性（Cdyn），用力肺活量（FVC），0.4 s率（FEV0.4/FVC%），呼气峰值流速（PEF），最大呼气中期流速（MMF），计算质量FVC；称量脏器质量和大鼠体质量，计算脏器系数；用血气分析仪检测腹主动脉酸碱度（pH），氧分压（PO2），二氧化碳分压（PCO2），氧饱和度（SO2）；用酶联免疫吸附法（ELISA）检测血清中肾素，前列腺素E2（PGE2），基质金属蛋白酶-1（MMP-1）含量；取左肺进行马松（Masson）染色观察肺组织的病理变化。结果：与正常组比较，气管内注射5 mg·kg-1博莱霉素能够明显增加SD大鼠肺脏质量和肺脏系数（P<0.05），降低Cydn，FVC和质量FVC（P<0.05），增加Ri（P<0.05），升高FEV0.4/FVC%（P<0.05），升高腹主动脉血中PCO2水平（P<0.05），明显降低PO2，SO2水平（P<0.05），升高血清中PGE2水平（P<0.05），病理显示模型大鼠肺组织形成大量实变区，发生实变的肺组织以细胞异常增殖为主的非纤维化区和伴有大量细胞外基质沉积的纤维化区为主。与模型组相比，右归饮中剂量组肺脏质量明显回落（P<0.05），Cydn，FVC和质量FVC回升（P<0.05），Ri，FEV0.4/FVC%下降（P<0.05），血清中PGE2水平下降（P<0.05）；右归饮高剂量组能够明显升高动脉血中PO2，SO2水平（P<0.05）。病理显示右归饮中剂量组能够抑制肺组织实变区向非实变区的炎性浸润。结论：右归饮能够改善实验性肺纤维化SD大鼠的肺功能，与右归饮降低血清中PGE2水平，抑制炎性浸润区的扩散，延缓纤维化进程有关。

Abstract

Objective: To investigate the efficacy and mechanism of Youguiyin

a representative decoction of tonifying kidney yang

in the rats with bleomycin induced pulmonary fibrosis. Method: A total of 25 SPF male rats were divided into five groups by the method of random number table

namely normal group

model group

as well as Youguiyin high

medium and low dose groups

with 5 rats in each group. Pulmonary fibrosis models were established by intratracheal injections of bleomycin(5 mg·kg-1)

and the rats were treated with high

medium and low doses (20

5 g·kg-1) of Youguiyin for 14 days from day 15 after modeling. Then the inspiratory resistance (Ri)

expiratory resistance (Re)

lung compliance (Cdyn)

forced vital capacity (FVC)

0.4 second rate (FEV0.4/FVC%)

peak expiratory flow rate (PEF)

and maximum mid expiratory flow velocity (MMF) were tested by animal lung function instrument

and FVC/lung weight were calculated; the weights of organs were recorded and the organ coefficient was calculated. The pH values of abdominal aorta (pH)

oxygen partial pressure (PO2)

carbon dioxide pressure (PCO2)

oxygen saturation (SO2) were detected by blood gas analyzer. Renin

prostaglandin E2 (PGE2) and matrix metalloproteinase-1 (MMP-1) levels in serum were measured with enzyme linked immunosorbent assay (ELISA). Histopathological abnormalities in left lungs were evaluated by Masson's trichrome stain. Result: As compared with the normal group

intratracheal injection of 5 mg·kg-1 bleomycin can significantly increase the lung weight and lung coefficient (P< 0.05)

decrease Cdyn

FVC and FVC/lung weight (P< 0.05)

increase Ri (P< 0.05)

increase FEV0.4/FVC% (P< 0.05)

increase PCO2 in abdominal aortic blood (P< 0.05)

decrease PO2 and SO2 significantly (P< 0.05)

and increase PGE2 levels in serum (P< 0.05) of SD rats. Pathological examination of lung tissues showed large area of consolidation in lung tissue of model rats

and those lung tissues with consolidation were mostly formed by the non-fibrosis area with abnormal cell proliferation and fibrosis area with a large number of extracellular matrix deposition. As compared with the model group

Youguiyin medium dose group decreased the lung weight significantly (P<0.05)

increased Cydn

FVC and FVC/lung (P<0.05)

decreased Ri and FEV0.4/FVC% (P<0.05)

decreased PGE2 levels (P< 0.05); while PO2 and SO2 levels in arterial blood were significantly increased in high dose group (P<0.05). Pathological examination showed Youguiyin can inhibit chronic inflammatory infiltration from pulmonary consolidation to normally aerated lung parenchyma. Conclusion: Youguiyin could improve the pulmonary function of model rats

which may be associated with lowing PGE2 in serum

inhibiting the diffusion of chronic inflammatory infiltration

and delaying pulmonary fibrosis.

关键词

Keywords

references

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Investigating Mechanism of Fritillariae Cirrhosae Bulbus Against Pulmonary Fibrosis Based on Spatial Metabolomics

Protective Effects of Dengzhan Shengmai Capsules against Bleomycin-induced Pulmonary Fibrosis in C57BL/6 Mice

Bufei Tongbi Decoction Inhibits Pulmonary Fibrosis in Diabetic Rats via TGF-β₁/p-Smad3 Signaling Pathway

Effect of Cannabidiol on Pulmonary Fibrosis Analyzed by UPLC-Q-TOF-MS

Related Author

QIN Shanbo

TAN Peng

HAO Lu

XIE Junjie

LIN Junzhi

ZHANG Lei

ZHAO Junning

ZENG Qiang

Related Institution

TCM Regulating Metabolic Diseases Key Laboratory of Sichuan Province，Hospital of Chengdu University of TCM

College of Food and Biological Engineering， Chengdu University

Key Laboratory of Biological Evaluation of Traditional Chinese Medicine（TCM） Quality of National Administration of TCM，Sichuan Academy of Chinese Medicine Sciences

Affiliated Hospital of Chengdu University of Traditional Chinese Medicine

Zigong First People's Hospital

AI问答

Postal code：100700
Tel：010-84076882 Email：syfjx_2010@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰